Altor BioScience Corporation (Altor), a leading developer of cancer immunotherapeutics, announced enrollment is complete for the first cohort in a Phase 1b/2 trial using ALT-803, a proprietary interleukin-15 (IL-15) superagonist protein complex, in combination with the approved anti-PD-1 antibody (Ab) nivolumab (Opdivo®; Bristol-Myers Squibb) for patients with pre-treated, advanced, or metastatic non-small cell lung cancer (NSCLC). This Investigator-Sponsored Trial is being conducted under the direction of John Wrangle, M.D., M.P.H., at the Medical University of South Carolina (MUSC).
ALT-803 is considered one of the most promising novel immunotherapeutic agents for treating multiple types of cancers and viral infections. Extensive pre-clinical studies have shown that ALT-803 activates the immune system to mobilize lymphocytes against tumor cells and could potentially serve as an important backbone therapy for applications in combination treatments. Studies are currently being conducted to evaluate the synergy of ALT-803 combined with other cancer therapies, including immune checkpoint inhibitor drugs. Results from these studies also suggest that ALT-803, in combination with immune checkpoint inhibitors, including anti-PD-1 Ab, may lead to enhanced immunostimulatory responses against various cancer indications.